U.S. Markets for Addiction & Substance Abuse Treatment
- The U.S. market for substance abuse treatment and diagnosis increased slightly from $2.6 billion in 2007 to $2.7 billion in 2008. It should reach $3.1 billion in 2013, for a compound annual growth rate (CAGR) of 2.7%.
- Pharmaceutical treatments have the largest share of the market, worth $2.4 billion in 2007 and $2.5 billion in 2008. This should reach $2.8 billion in 2013, for a CAGR of 2.3%.
- Diagnostic testing is the second largest market segment, generating $216.0 million in 2007 and $230.0 million in 2008. This segment is expected to increase at a CAGR 5.9% to reach $307.0 million in 2013.
STUDY GOALS AND OBJECTIVES
This BCC Research report details the complicated world of substance abuse. The increased prevalence of substance abuse poses a threat to the health and welfare of many populations throughout the world. Recreational drugs play a major role in crime and corruption and are becoming a larger problem each year. Abuse of prescription drugs and alcohol places a heavy burden on health resources due to the subsequent medical problems. Breaking the substance abuse cycle is a difficult and tedious process. Pharmaceutical manufacturers have developed several products to assist in recovery from substance abuse. Those products are detailed in the report. Also discussed are the products to help employers, parents, social workers, and other groups and organizations detect for substance abuse.
The objectives of the study are to heighten the awareness of drug abuse and to identify preparations, tests, and important advancements in the drug abuse treatment arena. The study analyzes the new therapeutics and diagnostics for drug abuse treatment from a current standpoint as well as what is on the horizon. Manufacturers of pharmaceutical products have been reluctant to invest valuable time and resources into this market because of the issues facing the market. As a result, the problem of drug abuse continues to grow.
REASONS FOR DOING THE STUDY
This BCC study is presented to increase the awareness of substance abuse and identify pharmaceutical preparations that are used to treat addictions.
Because of the evolving nature of this important area of medicine, executives of substance abuse pharmaceuticals must remain ever vigilant to the changing environment and strive to keep abreast of new and currently used modalities in all facets of substance abuse treatment
SCOPE OF REPORT
The study is designed to be a comprehensive business tool that provides an in-depth look at the world of substance abuse treatments and diagnostics. The geographic scope of the report is the United States. The report identifies the different drugs of addiction; gives a brief explanation of the drug; outlines the characteristics of the drug; cites complications of the drug; presents current diagnostic testing; outlines current treatments, market size, and market participants; and discusses new developments and research. The report describes the industry in detail, its relationship to the healthcare industry, its economic consequences, its participants, and its trends for the future.
The following areas are addressed in this report:
- Cocaine, Crack
- Sedatives and Hypnotics
Each subsegment is discussed in detail, describing the drug, complications, diagnostic testing, therapeutic management, and current products on the market to treat abuse of the drug.
The information and analysis presented in this BCC Research report are based on extensive firsthand interviews with primary executives, product managers, and clinical specialists in the area of addiction and substance abuse. Background information was obtained from various government, business, medical journal, psychiatric journal and trade magazines; from statistics from the National Center on Drug Abuse; and from interviews with psychiatrists, psychologists, drug treatment counselors, and nurses. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as to formulate market projections.
All market data pertain to the U.S. market at the manufacturer’s level. Data are expressed in 2008 U.S. dollars. The base year was 2007. Historical data are provided for 2006 and forecast data are provided for 2008 and 2013. Historical, base year and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2007 base year.
Mary Anne Crandall is a seasoned medical analyst who has specialized in the pharmaceutical industry for the last 16 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the industry. Ms. Crandall is an RN and has a PhD in Natural Health.
The total U.S. market for substance abuse treatment and diagnostics reached $1.1 billion in 2003 and, rising at an AAGR (average annual growth rate) of 4.1%, will reach $1.3 billion in 2008.
The pharmaceutical treatments segment accounts for the largest portion of revenues with an estimated $922.1 million in 2003. By 2008, this segment is expected to reach $1.09 billion, growing at an average annual rate of 3.5%.
Diagnostic testing products account for about 15% of the market, or revenues of $162.8 million in 2003. Technological advancements are expected to result in average annual growth of 7.1%, raising revenues to $229.6 million by 2008.